Aura Biosciences
AURA
6.41
-0.06
-0.85%
Aura Biosciences
US · AURA
#3544 by market cap
Listed 2021
6.41
-0.06
-0.85%
Live - 5344 symbols - heartbeat 193s ago
· 2026-10-08 10:09
Pre-market
6.32
-2.19%
After-hours
6.46
0.00%
- Market cap
- 664.23M
- P/E (TTM)i
- -3.70
- P/Bi
- 2.11
- EPSi
- -1.76
- Div yieldi
- 0.00%
- 52W posi
- 35%
Reader sentiment
Are you bullish or bearish on AURA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.7 percentage points.
Institutional ownership
- Held by institutions
- 94.23% +0.74pp
- Institutions
- 178 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Hedge Fund35.67%
VC/PE Fund33.82%
Mutual Fund23.59%
Individual/Insider1.20%
Public Company0.69%
Private Company0.27%
Other4.57%
Top holders as of 2026-06-30
TCG Crossover Management, LLC
9.19% · 9.53M sh
Montanova Capital, LLC
6.95% · 7.21M sh
Frazier Life Sciences Management, LP
5.62% · 5.83M sh
Forbion Capital Partners B.V.
5.06% · 5.25M sh
Long Focus Capital Management LLC
4.94% · 5.12M sh
Vanguard Capital Management, LLC
4.57% · 4.74M sh
BlackRock
4.54% · 4.71M sh
Adage Capital Management, L.P.
4.47% · 4.64M sh
Caligan Partners, LP
4.14% · 4.30M sh
OrbiMed Advisors LLC
3.21% · 3.33M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 35 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| David Johnson | Independent Chairperson | 0.32% |
| Elisabet de los Pinos | Chief Executive Officer | 0.27% |
| Mark Plavsic | Chief Technology Officer | 0.24% |
| Amy Elazzouzi | Interim Principal Financial Officer & Interim Principal Accounting Officer | 0.14% |
| Anthony Gibney | Chief Financial & Business Officer | 0.08% |
| J. Hopkins | Chief Medical Officer & President of Research and Development | 0.06% |
| Conor Kilroy | General Counsel | 0.04% |
| Sapna Srivastava | Independent Director | 0.02% |
| Antony Mattessich | Independent Director | 0.02% |
| Julie Feder | Chief Financial Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Julie Person | Chief Human Resources Officer | Other Acquisition | +107,611 | -- |
| 2026-08-31 | Julie Person | Chief Human Resources Officer | Other Derivative Acquisition | +212,389 | $7.43 |
| 2026-08-31 | Erica Kratz | Chief Regulatory & Quality Officer | Other Acquisition | +100,885 | -- |
| 2026-08-31 | Erica Kratz | Chief Regulatory & Quality Officer | Other Derivative Acquisition | +199,115 | $7.43 |
| 2026-08-31 | J. Hopkins | Chief Medical Officer & President of Research and Development | Other Acquisition | +58,850 | -- |
| 2026-08-31 | J. Hopkins | Chief Medical Officer & President of Research and Development | Other Derivative Acquisition | +116,150 | $7.43 |
| 2026-08-31 | Amy Elazzouzi | Interim Principal Financial Officer & Interim Principal Accounting Officer | Other Acquisition | +23,540 | -- |
| 2026-08-31 | Amy Elazzouzi | Interim Principal Financial Officer & Interim Principal Accounting Officer | Other Derivative Acquisition | +46,460 | $7.43 |
| 2026-07-06 | Jeremy Bender | Independent Director | Other Acquisition | +30,000 | -- |
| 2026-07-06 | Jeremy Bender | Independent Director | Other Derivative Acquisition | +60,000 | $7.03 |
| 2026-06-30 | Conor Kilroy | General Counsel | Other Acquisition | +14,858 | -- |
| 2026-06-15 | Anthony Gibney | Chief Financial & Business Officer | Open Market Disposition | -12,824 | $6.42 |
| 2026-06-10 | Sapna Srivastava | Independent Director | Other Acquisition | +15,000 | -- |
| 2026-06-10 | Sapna Srivastava | Independent Director | Other Derivative Acquisition | +30,000 | $6.21 |
| 2026-06-10 | Antony Mattessich | Independent Director | Other Acquisition | +15,000 | -- |
| 2026-06-10 | Antony Mattessich | Independent Director | Other Derivative Acquisition | +30,000 | $6.21 |
| 2026-06-10 | David Johnson | Independent Chairperson | Other Acquisition | +15,000 | -- |
| 2026-06-10 | David Johnson | Independent Chairperson | Other Derivative Acquisition | +30,000 | $6.21 |
| 2026-06-10 | Teresa Marie Bitetti | Director | Other Acquisition | +15,000 | -- |
| 2026-06-10 | Teresa Marie Bitetti | Director | Other Derivative Acquisition | +30,000 | $6.21 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:09:53 · For reference only, not investment advice and not tailored to your situation.